Catalog Home Page

Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis

Doyle, J.F. and Ho, K.M. (2009) Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis. Mayo Clinic Proceedings, 84 (3). pp. 234-242.

Link to Published Version: http://dx.doi.org/10.4065/84.3.234
*Subscription may be required
Free to read: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26645...
*No subscription required

Abstract

OBJECTIVE
To assess whether amiodarone, as part of a strategy to achieve sinus rhythm, is safe and effective compared with a placebo or rate control drug in patients with persistent atrial fibrillation (AF) of more than 30 days' duration.

METHODS
Randomized controlled trials comparing amiodarone with a placebo or rate control drug were identified through the EMBASE (January 1, 1988, to October 18, 2008), MEDLINE (January 1, 1966, to October 18, 2008), and Cochrane Controlled Trials Register (second issue 2008) databases with no language restrictions.

RESULTS
Twelve randomized controlled trials that involved a total of 5060 patients with persistent AF were considered. Amiodarone was more effective than a placebo or rate control drug in achieving sinus rhythm (21.3 vs 9.2 per 100 patient-years in sinus rhythm; relative risk [RR], 3.2; 95% confidence interval [CI], 1.9-5.5), and its use was not associated with an increased risk of long-term mortality (4.7 vs 3.9 per 100 patient-years; RR, 0.95; 95% CI, 0.8-1.1; P=.51; I2=0%). Cessation of amiodarone therapy because of intolerable adverse effects was more common compared with a placebo or rate control drug (10.7 vs 1.9 per 100 patient-years; RR, 3.0; 95% CI, 1.4-6.2; P<.001; I2=70%), but amiodarone was not associated with an increased incidence of hospitalizations (RR, 1.1; 95% CI, 0.6-2.1; P=.77; I2=90%).

CONCLUSION
Amiodarone, as part of a strategy to achieve and maintain sinus rhythm, appears to be safe and effective in patients with persistent AF. However, some patients may not tolerate the adverse effects of this agent.

Publication Type: Journal Article
Publisher: Elsevier
Copyright: © 2009 Mayo Foundation for Medical Education and Research
URI: http://researchrepository.murdoch.edu.au/id/eprint/34282
Item Control Page Item Control Page